Bill

Ginkgo Bioworks Reports First Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
Public, Safety, Burn, Cell, Webcast, Forecasting, Cell engineering, Automation, DNA, Bill, G&A, Growth, Mobile phone

BOSTON, May 9, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2024. The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Key Points: 
  • Initiatives include a reduction of $200 million in annualized run-rate operating expenses by mid-2025, with anticipated substantial reduction occurring in 2024
    BOSTON, May 9, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2024.
  • The update, including a webcast slide presentation with additional details on the first quarter and supplemental financial information, will be available at investors.ginkgobioworks.com .
  • This trend needs to change, and we are simplifying both what we sell to customers and how we do the work that drives revenue at Ginkgo.
  • Ginkgo revised its expectation for Cell Engineering services revenue to $120-140 million in 2024.

Carna Health Names Leadership Team and Presents Strong Results from Bermuda CKD Screening Program

Retrieved on: 
Donnerstag, Mai 9, 2024
Software, Telemedicine, Virtual Medicine, General Health, Health, Artificial Intelligence, Health Technology, Technology, Other Health, Mortality, Public, Kidney disease, Nephrology, Hospital, Prevalence, Death, Partnership, MSBA, Oscar Health, Joslin Diabetes Center, Intelligence, CKD, Patient, Bill, MPH, Dialysis, Faculty, Ministry, Harvard Medical School, MBA, BBA, Quality of life, Chronic kidney disease, MHA, IBM, Management

Carna Health , a digital health company transforming kidney care, today named its leadership team and released results from a chronic kidney disease (CKD) screening program in Bermuda as the first international recipient of a grant from the Bermuda Health Council Innovation Program.

Key Points: 
  • Carna Health , a digital health company transforming kidney care, today named its leadership team and released results from a chronic kidney disease (CKD) screening program in Bermuda as the first international recipient of a grant from the Bermuda Health Council Innovation Program.
  • “Our shared commitment with Carna Health to develop new screening and monitoring programs for CKD at sites outside the hospital is essential to our partnership.
  • “The results from the screening program in Bermuda demonstrate the feasibility of cost-effective, large-scale population screening and monitoring for CKD – and the high rate of undiagnosed CKD that needs to be addressed so we can prioritize prevention and earlier disease management,” said Carna Health CMO and COO Shika Pappoe, MD, MPH, MBA.
  • In just three days the program surpassed its screening target, drawing more than 550 participants.

Aeonsemi Unveils Nemo™ Platform: Revolutionizing In-Vehicle Networking with Multi-Gigabit Ethernet

Retrieved on: 
Mittwoch, Mai 8, 2024
Hardware, IOT (Internet of Things), Semiconductor, Automotive Manufacturing, Manufacturing, Technology, EV, Electric Vehicles, Autonomous Driving, Vehicles, Artificial Intelligence, General Automotive, Other Technology, Automotive, Networks, Vehicle Technology, Mobile, Wireless, Advanced driver-assistance system, TSN, Ethernet, Architecture, EEE, BOM, IEEE, Radar, Software, PHY, ADAS, FSD, Power, Energy-Efficient Ethernet, Weight, Original equipment manufacturer, Time-Sensitive Networking, POC, Bill, Physics, Lidar, SerDes, Compound annual growth rate, Instrumentation

Aeonsemi, a leader in high-speed Ethernet ICs, is entering the automotive market with the introduction of Nemo™, industry’s most complete IEEE 802.3ch compliant multi-Gigabit Ethernet chipset for In-Vehicle Networking (IVN) applications.

Key Points: 
  • Aeonsemi, a leader in high-speed Ethernet ICs, is entering the automotive market with the introduction of Nemo™, industry’s most complete IEEE 802.3ch compliant multi-Gigabit Ethernet chipset for In-Vehicle Networking (IVN) applications.
  • Ethernet has emerged as the technology of choice in automotive networking.
  • They rely on proprietary point-to-point SerDes technology due to the lack of high-speed, low-power, cost-effective asymmetrical Ethernet solutions.
  • For more information about the Nemo™ chipset and how it can transform in-vehicle networking, visit Aeonsemi's website or contact [email protected] .

Red Nose Day Giving Away Larger-Than-Life Prizes Inspired by Childhood Dreams with Childhood Dreamstakes Campaign

Retrieved on: 
Mittwoch, Mai 8, 2024
Education, EBay, Organization, FUN, Health, Hope, Candy, Monster truck, Dream, Happiness, King Features Syndicate, The Lego Group, Comic Relief, NBC, Poverty, Wall, Bill, Child, Music, National park, Snapple, Creative director, Red Nose, Change, Comics, Toy

NEW YORK, May 8, 2024 /PRNewswire/ -- Red Nose Day, the beloved fundraising campaign by Comic Relief US to help end child poverty, today announced Childhood Dreamstakes, a larger-than-life campaign that gives entrants the chance to relive the joy, wonder, and adventure of being a kid. Starting today through June 3, everyone who donates to enter at rednoseday.org has the chance to win one of six dream prizes all to support one very serious mission – ending childhood poverty.

Key Points: 
  • Childhood Dreamstakes is one of many ways to engage in the Red Nose Day campaign this year.
  • Artists from across the musical spectrum will join a month-long fundraiser called the Red Nose Day Childhood Sing-a-long.
  • This year, it's easier than ever to step into the spirit of Red Nose Day with a fun, free, and all-new digital Red Nose Day USA filter .
  • "Childhood Dreamstakes – and Red Nose Day 2024 – are all about creating that hope and remembering what's so special about childhood.

NANITE AWARDED $1.8M TO DEVELOP AI-DRIVEN GENE THERAPY FOR HIV

Retrieved on: 
Mittwoch, Mai 8, 2024
Nuclear power plant, Doctor of Philosophy, Research, Success, Nanoparticle, Therapy, Bill, Melinda French Gates, HIV, Pharmaceutical industry

BOSTON, May 8, 2024 /PRNewswire/ -- Nanite, Inc. today announced a $1.8M grant from the Bill & Melinda Gates Foundation to design and optimize polymeric delivery vehicles to deliver DNA-encoded therapeutics.

Key Points: 
  • Nanite's proprietary SAYERTM platform combines AI-driven polymer design with multiplexed in vivo screening to develop best-in-class polymer nanoparticles [PNPs] for tissue-specific delivery.
  • Success would represent a significant breakthrough in HIV management, particularly in populations with limited access to medical care.
  • "One of our long-stated goals is to develop technologies that allow the benefits of gene therapy to be accessible to a wider patient population, particularly in underserved communities.
  • Nanite is dedicated to accelerating the impact of genetic medicine for the treatment of HIV."

Utimaco Extends Trust as a Service Cloud Marketplace with General Purpose HSM

Retrieved on: 
Montag, Mai 6, 2024
Timestamp, Organization, Internet of things, Service, General-purpose, Partnership, Trust, Conference, Sophos, Bill, Motion, HSM, Key Exchange, RSA, Payment

AACHEN, Germany, May 6, 2024 /PRNewswire/ -- RSA Conference 2024 (Booth #5256) -- Utimaco, a leading global provider of IT security solutions, today announced its expanded Trust as a Service marketplace with new features and deployment options. The enhanced marketplace enables businesses to choose between on-premises or cloud-based options seamlessly in a single-pane view. Utimaco's General Purpose Hardware Security Module (HSM) as a Service allows customers to reduce capital and labor costs without the need for a dedicated server room, secure environment set-up, or data center selection.

Key Points: 
  • Utimaco's General Purpose Hardware Security Module (HSM) as a Service allows customers to reduce capital and labor costs without the need for a dedicated server room, secure environment set-up, or data center selection.
  • Trust as a Service offers customers:
    Reduced total cost of ownership – Eliminates on-site expenses and hardware investments while also cutting down hardware and staffing costs.
  • Mathias T. Eng, CEO, PROREGIA, said: "Choosing Utimaco's General Purpose HSM as a Service allowed us to extend our security services to legacy devices with severe hardware and software constraint.
  • Hacan Tiwemark, chief operating officer, Utimaco, said: "With the enhanced Trust as a Service marketplace, we're providing our customers with an interconnected service offering that empowers them to manage their cybersecurity needs online and flexibly.

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact

Retrieved on: 
Montag, Mai 6, 2024
Climate change, Agriculture, Risk, Climate, Health, Infection, AMR, Partnership, Research, Vaccine, History, Disease, Attention, Science, Urinary tract infection, Poverty, Mental health, Bill, Melinda French Gates, Notifiable disease, Novo Nordisk Foundation, Immunity, Tuberculosis, Prevalence, Global health, Pharmaceutical industry

HELSINGØR, Denmark, May 6, 2024 /PRNewswire/ -- The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

Key Points: 
  • The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million.
  • "By pooling the vast experience and unique expertise of each organization—across research, technology, innovation, and enterprise—we can make advances that wouldn't otherwise be possible," said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation.
  • To better protect people globally from the devastating effects of climate change on health, solutions that draw across climate, health, and agricultural science will be needed.
  • By partnering with the Novo Nordisk Foundation and the Gates Foundation, we can raise ambition, and combine resources and networks to find new ways to advance global health research—especially for those with greatest need."

The Bradford Exchange Mint Celebrates the Royal Succession

Retrieved on: 
Montag, Mai 6, 2024
The Bradford Exchange, Bill, Catholic Church, Protestantism, HRM, 117th United States Congress, Death, Church, Male, Sovereign, Royal Highness, Princess Sophia, Parliament, Gold, State Emblem of India, Royal, Government, Order of succession, HRH, Bill of Rights, Jewellery

NILES, Ill., May 6, 2024 /PRNewswire/ -- To mark the first anniversary of King Charles III's Coronation, The Bradford Exchange Mint is proud to announce a very special opportunity to acquire a minted tribute to depict three generations of Royal Succession.

Key Points: 
  • NILES, Ill., May 6, 2024 /PRNewswire/ -- To mark the first anniversary of King Charles III's Coronation, The Bradford Exchange Mint is proud to announce a very special opportunity to acquire a minted tribute to depict three generations of Royal Succession.
  • All three appear together for the very first time on a coin minted by The Commonwealth Mint of the UK, on an exclusive Bradford Exchange commemorative.
  • The British royal succession was established by the Bill of Rights (1689) and the Act of Settlement (1701), after King James II fled the country.
  • The reverse of our coin features an engraved design of the Royal Seal of England along with the words His Royal Highness, William, Prince of Wales.

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact

Retrieved on: 
Montag, Mai 6, 2024
Climate change, Agriculture, Risk, Climate, Health, Infection, AMR, Partnership, Research, Vaccine, History, Disease, Attention, Science, Urinary tract infection, Poverty, Mental health, Bill, Melinda French Gates, Notifiable disease, Novo Nordisk Foundation, Immunity, Tuberculosis, Prevalence, Global health, Pharmaceutical industry

HELSINGØR, Denmark, May 6, 2024 /PRNewswire/ -- The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and innovation to advance solutions that are accessible and affordable to people in low- and middle-income countries (LMICs).

Key Points: 
  • The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million.
  • "By pooling the vast experience and unique expertise of each organization—across research, technology, innovation, and enterprise—we can make advances that wouldn't otherwise be possible," said Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation.
  • To better protect people globally from the devastating effects of climate change on health, solutions that draw across climate, health, and agricultural science will be needed.
  • By partnering with the Novo Nordisk Foundation and the Gates Foundation, we can raise ambition, and combine resources and networks to find new ways to advance global health research—especially for those with greatest need."

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 2, 2024
AIDS, Health, Infectious Diseases, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, Infection, HIV Vaccine Trials Network, Administration, Cirrhosis, ASPR, Bangladesh Technical Education Board, Congress, HHS, COVID, EASL, Investment, Safety, Peginterferon-alfa, Abstract, MedRxiv, Development, Hepatitis, GSK, Vir, HCMV, Bill, Data analysis, Influenza, Conditional sentence, HIV, MBA, Metapneumovirus, Vaccine

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
  • The Phase 2 MARCH Part B trial is fully enrolled with 48-week end of treatment data expected in the fourth quarter of 2024.
  • Cash, cash equivalents and investments declined by approximately $118 million during the first quarter of 2024.
  • Revenues: Total revenues for the quarter ended March 31, 2024, were $56.4 million compared to $63.0 million for the same period in 2023.